. 2021 Apr 20;99(6):1275–1279. doi: 10.1016/j.kint.2021.04.007

Table 1.

Characteristics of studies examining immune response to COVID-19 infection and the response to the COVID-19 vaccines among patients with ESKD receiving kidney replacement therapy

Author	Patient population	Infection vs. vaccine	Sample size	Follow-up	Outcome	Result
Clark et al.³	MHD	Infection	136	6 mo	Anti-NP Anti-RBD	85% Seropositive; 70% T-cell response in seronegative patients

Forbes et al.⁴	MHD	Infection	122	184 d	Anti-NP	100% Seropositive
						Increasing Ab over time

Anft et al.⁵	MHD and control	Infection	14 and 14	Not provided	T-cell response	Robust response in MHD

Canas et al.⁶	MHD/pediatric patients	Infection	14	13 wk	Anti-S IgG	38% Seropositive

Torreggiani et al.⁷	MHD	Vaccine/Pfizer	101	3 wk after first vaccination	Anti-S IgG	35% Seropositive

Billany et al.⁸	MHD	Vaccine/Pfizer + AZ	94	28 d after first dose	Anti-S IgG	80% Seropositive

Attias et al.⁹	MHD	Vaccine/Pfizer	69	Weekly until 3 wk after second dose	Anti-S IgG	80% Seropositive previous infection better response after first dose

Simon et al.¹⁰	MHD and control	Vaccine/Pfizer	81 and 80	3 wk after second vaccine	Anti-NP	Low titers in MHD (171 vs. 478)

Berar Yanar et al.¹¹	MHD, PD, and control	Vaccine/Pfizer	127, 33, and 132	21–35 d after the second dose	Anti-S IgG	Low titers in dialysis patients, 6 de novo infections in dialysis patients

Boyarsky et al.¹²	Kidney Tx	Vaccine/both mRNA vaccines	436	20 d	Anti-S IgG	17% Seropositive

Benotmane et al.¹³	Kidney Tx	Vaccine/mRNA 1273	242	28 d	Anti-S IgG	11% Seropositive

Benotmane et al.¹⁴	Kidney Tx	Vaccine/mRNA 1273	205	28 d after second dose	Anti-S IgG	48% Seropositive

AZ, AstraZeneca; COVID-19, coronavirus disease 2019; ESKD, end-stage kidney disease; MHD, maintenance hemodialysis; NP, nucleocapsid protein; PD, peritoneal dialysis; RBD, receptor-binding domain; S, spike; Tx, transplantation.